Discovery of GlyT1 inhibitors with improved pharmacokinetic properties

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 5, 2009, Pages 1492-1495

  Wolkenberg, Scott E ^a   Zhao, Zhijian ^a   Wisnoski, David D ^a   Leister, William H ^a   O'Brien, Julie ^a   Lemaire, Wei ^a   Williams Jr , David L ^a   Jacobson, Marlene A ^a   Sur, Cyrille ^a   Kinney, Gene G ^a   Pettibone, Doug J ^a   Tiller, Philip R ^a   Smith, Sheri ^a   Gibson, Christopher ^a   Ma, Bennett K ^a   Polsky Fisher, Stacey L ^a   Lindsley, Craig W ^a   Hartman, George D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cassette dosing; GlyT1; NMDA pharmacokinetics; Schizophrenia

Indexed keywords

GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 1 INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG STABILITY; DRUG SYNTHESIS; NONHUMAN; PHARMACOKINETICS; PROTEIN TARGETING; RAT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOGS; DRUG DISCOVERY; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MICE; MICE, INBRED DBA; N-METHYLASPARTATE; PIPERIDINES; RATS; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 60449093902     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.015     Document Type: Article

References (20)

1. Seeman P., Lee T., Chau-Wong M., and Wong K. Nature 261 (1976) 717
2. Seeman P., and Lee T. Science 188 (1975) 1217
3. Lindsley C.W., Shipe W.D., Wolkenberg S.E., Theberge C.R., Williams D.L., Sur C., and Kinney G.G. Curr. Top. Med. Chem. 6 (2006) 771
4. Andreasen N.C. Brain Res. Rev. 31 (2000) 106
5. Javitt D.C., and Zukin S.R. Am. J. Psychiatry 148 (1991) 1301
6. Olney J.W., and Farber N.B. Arch. Gen. Psychiatry 52 (1995) 998
7. Olney J.W., Newcomer J.W., and Farber N.B. J. Psychiatry Res. 33 (1999) 523
8. Marino P.J., and Conn P.J. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 1
9. Sur C., and Kinney G.G. Expert Opin. Investig. Drugs 13 (2004) 515 and references therein
10. Lindsley C.W., Zhao Z., Leister W.H., O'Brien J., Lemaire W., Williams D.L., Chen T.-B., Chang R.S.L., Burno M., Jacobson M.A., Sur C., Kinney G.G., Pettibone D.J., Tiller P.R., Smith S., Tsou N.N., Duggan M.E., Conn P.J., and Hartman G.D. Chem. Med. Chem. 1 (2006) 807
11. Zhao Z., Leister W.H., O'Brien J.A., Lemaire W., Williams D.L., Jacobson M.A., Sur C., Kinney G.G., Pettibone D.J., Tiller P.R., Smith S., Hartman G.D., Lindsley C.W., and Wolkenberg S.E. Bioorg. Med. Chem. Lett. 19 (2009) 1488
12. Compound 9 was prepared by an alternative route employing a Strecker reaction of N-benzyl-4-piperidone and azetidine.
13. Pinard E., Ceccarelli S.M., Stalder H., and Alberati D. Bioorg. Med. Chem. Lett. 16 (2006) 349
14. Ceccarelli S.M., Pinard E., Stalder H., and Alberati D. Bioorg. Med. Chem. Lett. 16 (2006) 354
15. Berman J., Halm K., Adkison K., and Shaffer J. J. Med. Chem. 40 (1997) 827
16. Shaffer J.E., Adkison K.K., Halm K., Hedeen K., and Berman J. J. Pharm. Sci. 88 (1999) 313
17. White R.E., and Manitpisitkul P. Drug Metab. Dispos. 29 (2001) 957
18. The absolute configuration of 21 was confirmed by single X-ray crystal analysis (anomalous dispersion).
19. Yamazaki M., Neway W.E., Ohe T., Chen I.-W., Rowe J.F., Hochman J.H., Chiba M., and Lin J.H. J. Pharmacol. Exp. Ther. 296 (2001) 723
20. Zeng Z., O'Brien J.A., Lemaire W., O'Malley S.S., Miller P.J., Zhao Z., Wallace M.A., Raab C., Lindsley C.W., Sur C., and Williams D.L. Nucl. Med. Biol. 35 (2008) 315